1 day Ago By ABMN Staff
Bank of New York Mellon Corp decreased its holdings in Outset Medical, Inc. ( NASDAQ:OM – Free Report ) by 35.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission.
The fund owned 495,376 shares of the company’s stock after selling 276,155 shares during the quarter. Bank of New York Mellon Corp owned 0.96% of Outset Medical worth $1,907,000 at the end of the most recent reporting period.
Several other large investors have also added to or reduced their stakes in the company. Griffin Asset Management Inc. boosted its position in shares of Outset Medical by 7.
8% during the second quarter. Griffin Asset Management Inc. now owns 105,514 shares of the company’s stock worth $406,000 after acquiring an additional 7,600 shares during the last quarter.
Assenagon Asset Management S.A. raised its stake in Outset Medical by 60.
4% during the second quarter. Assenagon Asset Management S.A.
now owns 1,515,126 shares of the company’s stock valued at $5,833,000 after purchasing an additional 570,281 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its stake in Outset Medical by 29.
7% during the first quarter. Jacobs Levy Equity Management Inc. now owns 398,006 shares of the company’s stock valued at $884,000 after purchasing an additional 91,256 shares in the last quarter.
Price T Rowe Associates Inc. MD raised its stake in Outset Medical by 75.3% during the first quarter.
Price T Rowe Associates Inc. MD now owns 82,636 shares of the company’s stock valued at $184,000 after purchasing an additional 35,495 shares in the last quarter. Finally, Lazard Asset Management LLC raised its stake in Outset Medical by 103.
7% during the first quarter. Lazard Asset Management LLC now owns 523,860 shares of the company’s stock valued at $1,162,000 after purchasing an additional 266,717 shares in the last quarter. Outset Medical Price Performance NASDAQ:OM opened at $0.
53 on Wednesday. The company has a debt-to-equity ratio of 2.87, a current ratio of 6.
80 and a quick ratio of 5.38. The firm has a market cap of $27.
66 million, a price-to-earnings ratio of -0.16 and a beta of 1.92.
The company has a 50 day moving average price of $1.99 and a 200-day moving average price of $2.73.
Outset Medical, Inc. has a 1-year low of $0.44 and a 1-year high of $12.
45. Wall Street Analyst Weigh In OM has been the topic of several recent analyst reports. Royal Bank of Canada downgraded shares of Outset Medical from an “outperform” rating to a “sector perform” rating and reduced their target price for the company from $6.
00 to $3.00 in a research note on Thursday, August 8th. TD Cowen dropped their target price on shares of Outset Medical from $9.
00 to $3.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the stock.
According to data from MarketBeat.com, Outset Medical has an average rating of “Hold” and a consensus price target of $4.64.
Check Out Our Latest Stock Report on OM About Outset Medical ( Free Report ) Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. Recommended Stories Receive News & Ratings for Outset Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outset Medical and related companies with MarketBeat.
com's FREE daily email newsletter ..
